Patient-derived micro-organospheres enable clinical precision oncology.

Journal Article (Journal Article)

Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of micro-organospheres (MOSs) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of recently diagnosed metastatic colorectal cancer (CRC) patients using an MOS-based precision oncology pipeline reliably assessed tumor drug response within 14 days, a timeline suitable for guiding treatment decisions in the clinic. Furthermore, MOSs capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

Full Text

Duke Authors

Cited Authors

  • Ding, S; Hsu, C; Wang, Z; Natesh, NR; Millen, R; Negrete, M; Giroux, N; Rivera, GO; Dohlman, A; Bose, S; Rotstein, T; Spiller, K; Yeung, A; Sun, Z; Jiang, C; Xi, R; Wilkin, B; Randon, PM; Williamson, I; Nelson, DA; Delubac, D; Oh, S; Rupprecht, G; Isaacs, J; Jia, J; Chen, C; Shen, JP; Kopetz, S; McCall, S; Smith, A; Gjorevski, N; Walz, A-C; Antonia, S; Marrer-Berger, E; Clevers, H; Hsu, D; Shen, X

Published Date

  • June 2, 2022

Published In

Volume / Issue

  • 29 / 6

Start / End Page

  • 905 - 917.e6

PubMed ID

  • 35508177

Pubmed Central ID

  • PMC9177814

Electronic International Standard Serial Number (EISSN)

  • 1875-9777

Digital Object Identifier (DOI)

  • 10.1016/j.stem.2022.04.006


  • eng

Conference Location

  • United States